innoscripta SE has announced its financial results for the first half of 2026, showing a robust 43% increase in revenue compared to the same period in 2025, reaching EUR 63.1 million. The company's adjusted EBIT rose by 49% to EUR 36.4 million, with an adjusted EBIT margin of 57.7%. These figures underscore the company's successful execution of its growth strategy, particularly in the context of the German R&D tax allowance (Forschungszulage), which remains a key driver. The number of customers has grown to over 2,900 during this period.
Central to this growth is the further development of Clusterix, innoscripta's scalable software platform for managing research and development activities. The platform has been strengthened as the central infrastructure for project structuring, data management, and application submissions. This enhancement enables automated data validation, higher data quality, and faster, more standardized processes. Importantly, Clusterix facilitates consistent workflows across different markets, providing a technological foundation for international scaling. Its flexibility in adapting to various regulatory requirements is crucial for efficient entry into new markets.
The first half of 2026 also saw significant progress in international expansion. The company opened an office in Hamburg, Germany, and made its first foray into France with a location near Toulouse, where it has already secured customers. In the UK, innoscripta entered the market with a Manchester office as of July 1, 2026, and has begun serving clients in the United States, a high-growth market. These moves are part of a deliberate strategy to leverage Clusterix's capabilities to meet diverse regulatory demands and capture new opportunities.
Given the strong performance and the continued momentum, the Management Board of innoscripta has confirmed its guidance for the full year 2026. The company expects group revenue of at least EUR 140 million and EBIT of at least EUR 80 million, assuming consistent timing of customer applications for R&D tax allowances. The company's half-year report, with detailed financial figures, is available on its website in the Investors section. Additionally, a virtual earnings call is scheduled for today at 3:00 p.m. CEST to discuss the results.
The results reflect innoscripta's ability to capitalize on the growing demand for digitized R&D management solutions. With a strong first half, the company is well-positioned to meet its annual targets and continue its expansion trajectory. As the platform evolves, it is set to play a pivotal role in enabling companies to efficiently manage innovation projects and make their R&D activities transparent and scalable.
